GM200

GM200 is an investigational biologic therapy being developed by GlycoMantra for the treatment of liver fibrosis and nonalcoholic steatohepatitis (NASH). GlycoMantra is a biotechnology company that focuses on developing glycan-based drugs, particularly galectin antagonists, to treat fibrosis, cancer, and diabetes. While GM200 is explicitly positioned in the company's pipeline for liver-related fibrotic conditions, its specific molecular target has not been publicly disclosed, distinguishing it from the company's lead candidate, GM100, which is a known Galectin-3 antagonist. GM200 represents an expansion of the company's biologics portfolio into chronic liver diseases characterized by inflammation and progressive scarring.